Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Bhavna OzaBhavna Oza, MBBS, MRC Clinical Trials Unit, UCL Institute of Clinical Trials and Methodology, London, United Kingdom; Tim Eisen, PhD, Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Grant D. Stewart, MBChB, Department of Surgery, University of Cambridge, Cambridge, United Kingdom; Axel Bex, MD, Division of Surgery and Interventional Science, Royal Free London NHS Foundation Trust UCL, London, United Kingdom, Netherlands Cancer Institute, Amsterdam, the Netherlands; Patrick Royston, DSc, MRC Clinical Trials Unit, UCL Institute of Clinical Trials and Methodology, London, United Kingdom; and Angela Meade, DPhil, MRC Clinical Trials Unit, UCL Institute of Clinical Trials and Methodology, London, United Kingdom.ORCID 0000-0003-3860-1349
Tim EisenBhavna Oza, MBBS, MRC Clinical Trials Unit, UCL Institute of Clinical Trials and Methodology, London, United Kingdom; Tim Eisen, PhD, Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Grant D. Stewart, MBChB, Department of Surgery, University of Cambridge, Cambridge, United Kingdom; Axel Bex, MD, Division of Surgery and Interventional Science, Royal Free London NHS Foundation Trust UCL, London, United Kingdom, Netherlands Cancer Institute, Amsterdam, the Netherlands; Patrick Royston, DSc, MRC Clinical Trials Unit, UCL Institute of Clinical Trials and Methodology, London, United Kingdom; and Angela Meade, DPhil, MRC Clinical Trials Unit, UCL Institute of Clinical Trials and Methodology, London, United Kingdom.ORCID 0000-0001-9663-4873
Grant D StewartBhavna Oza, MBBS, MRC Clinical Trials Unit, UCL Institute of Clinical Trials and Methodology, London, United Kingdom; Tim Eisen, PhD, Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Grant D. Stewart, MBChB, Department of Surgery, University of Cambridge, Cambridge, United Kingdom; Axel Bex, MD, Division of Surgery and Interventional Science, Royal Free London NHS Foundation Trust UCL, London, United Kingdom, Netherlands Cancer Institute, Amsterdam, the Netherlands; Patrick Royston, DSc, MRC Clinical Trials Unit, UCL Institute of Clinical Trials and Methodology, London, United Kingdom; and Angela Meade, DPhil, MRC Clinical Trials Unit, UCL Institute of Clinical Trials and Methodology, London, United Kingdom.ORCID 0000-0003-3188-9140
Axel BexBhavna Oza, MBBS, MRC Clinical Trials Unit, UCL Institute of Clinical Trials and Methodology, London, United Kingdom; Tim Eisen, PhD, Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Grant D. Stewart, MBChB, Department of Surgery, University of Cambridge, Cambridge, United Kingdom; Axel Bex, MD, Division of Surgery and Interventional Science, Royal Free London NHS Foundation Trust UCL, London, United Kingdom, Netherlands Cancer Institute, Amsterdam, the Netherlands; Patrick Royston, DSc, MRC Clinical Trials Unit, UCL Institute of Clinical Trials and Methodology, London, United Kingdom; and Angela Meade, DPhil, MRC Clinical Trials Unit, UCL Institute of Clinical Trials and Methodology, London, United Kingdom.ORCID 0000-0002-8499-2662
Patrick RoystonBhavna Oza, MBBS, MRC Clinical Trials Unit, UCL Institute of Clinical Trials and Methodology, London, United Kingdom; Tim Eisen, PhD, Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Grant D. Stewart, MBChB, Department of Surgery, University of Cambridge, Cambridge, United Kingdom; Axel Bex, MD, Division of Surgery and Interventional Science, Royal Free London NHS Foundation Trust UCL, London, United Kingdom, Netherlands Cancer Institute, Amsterdam, the Netherlands; Patrick Royston, DSc, MRC Clinical Trials Unit, UCL Institute of Clinical Trials and Methodology, London, United Kingdom; and Angela Meade, DPhil, MRC Clinical Trials Unit, UCL Institute of Clinical Trials and Methodology, London, United Kingdom.ORCID 0000-0001-6386-4410
Angela MeadeBhavna Oza, MBBS, MRC Clinical Trials Unit, UCL Institute of Clinical Trials and Methodology, London, United Kingdom; Tim Eisen, PhD, Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Grant D. Stewart, MBChB, Department of Surgery, University of Cambridge, Cambridge, United Kingdom; Axel Bex, MD, Division of Surgery and Interventional Science, Royal Free London NHS Foundation Trust UCL, London, United Kingdom, Netherlands Cancer Institute, Amsterdam, the Netherlands; Patrick Royston, DSc, MRC Clinical Trials Unit, UCL Institute of Clinical Trials and Methodology, London, United Kingdom; and Angela Meade, DPhil, MRC Clinical Trials Unit, UCL Institute of Clinical Trials and Methodology, London, United Kingdom.ORCID 0000-0001-6424-0554
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Reply to U. Capitanio et al. · full record | OpenQuestion